id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-P-4163-0006,FDA,FDA-2024-P-4163,"Determination That NOXAFIL (Posaconazole) Delayed-Release Tablets, 100 Grams Was Not Withdrawn From Sale for Reasons of
Safety or Effectiveness; Correction",Notice,Correction,2024-11-20T05:00:00Z,2024,11,2024-11-20T05:00:00Z,,2024-11-20T14:53:38Z,2024-27082,0,0,0900006486829fe2
FDA-2024-P-4163-0007,FDA,FDA-2024-P-4163,Final Response Letter from FDA CDER to Aizant Drug Research Solutions Private Limited,Other,Denial of Petition,2024-11-20T05:00:00Z,2024,11,2024-11-20T05:00:00Z,,2024-11-20T20:50:48Z,,0,0,090000648682ad8b
FDA-2024-P-4163-0005,FDA,FDA-2024-P-4163,"Determination That NOXAFIL (Posaconazole) Delayed-Release Tablets, 100 Grams Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2024-10-16T04:00:00Z,2024,10,2024-10-16T04:00:00Z,,2024-10-16T13:53:16Z,2024-23811,0,0,09000064867d07eb
FDA-2024-P-4163-0004,FDA,FDA-2024-P-4163,Amendment from Aizant Drug Research Solutions Private Limited,Other,Amendment,2024-09-04T04:00:00Z,2024,9,2024-09-04T04:00:00Z,,2024-09-04T21:29:05Z,,0,0,09000064866bef58
FDA-2024-P-4163-0002,FDA,FDA-2024-P-4163,Acknowledgement Letter from FDA DMS to Aizant Drug Research Solutions Private Limited,Other,Acknowledgement Letter/Receipt,2024-09-03T04:00:00Z,2024,9,2024-09-03T04:00:00Z,,2024-09-03T17:26:45Z,,0,0,09000064866bdf25
FDA-2024-P-4163-0001,FDA,FDA-2024-P-4163,Citizen Petition from Aizant Drug Research Solutions Private Limited,Other,Citizen Petition,2024-09-03T04:00:00Z,2024,9,2024-09-03T04:00:00Z,,2024-11-20T19:58:42Z,,0,0,09000064866bdf15
FDA-2024-P-4163-0003,FDA,FDA-2024-P-4163,Attachment 1,Supporting & Related Material,Background Material,2024-09-03T04:00:00Z,2024,9,,,2024-09-03T17:26:49Z,,0,0,09000064866bdf2b